Testing effectiveness (Phase 2)UnknownNCT05957757
What this trial is testing
RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression
Who this might be right for
Non-Muscle Invasive Bladder CancerHER2
RenJi Hospital 20